AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03758430 — intervention group
Intervention type: OTHER
Intervention: Meal-Tagging App
Description: Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
Study NCT03255096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
Study NCT03758430 — intervention group
Intervention type: DEVICE
Intervention: Fitness Tracker
Description: Fitness tracker will be worn around the clock for 16 weeks.
Study NCT03280641 — intervention group
Intervention type: DRUG
Intervention: Dabigatran Etexilate 110mg
Description: Dabigatran Etexilate 110mg, BID
Study NCT03280641 — intervention group
Intervention type: DRUG
Intervention: Warfarin Sodium
Description: Target INR:1.6-3.0
Study NCT02367534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical vein catheterization
Description: A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
Study NCT01412658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein mixture
Description: Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
Study NCT01412658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glycerol placebo
Description: Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - V - C+V
Description: Drug will be administered to according to C - V - C+V sequence for 3 period.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - C+V - V
Description: Drug will be administered to according to C - C+V - V sequence for 3 period.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V - C - C+V
Description: Drug will be administered to according to V - C - C+V sequence for 3 period.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V - C+V - C
Description: Drug will be administered to according to V - C+V - C sequence for 3 period.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C+V - C - V
Description: Drug will be administered to according to C+V - C - V sequence for 3 period.
Study NCT01838967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C+V - V - C
Description: Drug will be administered to according to C+V - V - C sequence for 3 period.
Study NCT02049749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate CARE
Description: CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
Study NCT01606761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
Study NCT01606761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
Study NCT01606761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
Study NCT01606761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
Study NCT01606761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
Study NCT02756650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
Study NCT03258346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inertial Load Cycling Training
Description: Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
Study NCT03258346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inertial Load Cycling Training
Description: Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
Study NCT03258346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: Subjects will consume 8oz of pomegranate juice daily for duration of study.
Study NCT03255096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
Study NCT03255096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
Study NCT03774459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ANAVEX2-73
Description: Active oral capsule
Study NCT01816984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01469260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
Study NCT03443817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele rehab
Description: Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time.
Study NCT01854528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT00521989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/90)
Description: CRx-102 dose 1
Study NCT00521989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone
Study NCT00521989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00521989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/180)
Description: CRx-102 dose 2
Study NCT00521989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/360)
Description: CRx-102 dose 3
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for >18 years on Days 5-33.
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: \*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40mg/m2/day divided BID (days 5 - 33)
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
Study NCT01854528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01854528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablet
Study NCT01854528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon a-2a (PegINF)
Description: Pre-filled syringe
Study NCT01854528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Film-coated tablet
Study NCT03774459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid dose ANAVEX2-73
Description: Active oral capsule
Study NCT03774459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule
Study NCT00874601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diovan® (valsartan)
Description: The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
Study NCT03830437 — intervention group
Intervention type: OTHER
Intervention: Evaluation of newborn stress
Description: Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
Study NCT03830437 — intervention group
Intervention type: OTHER
Intervention: Evaluation of body weight trend
Description: Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
Study NCT01696643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945
Study NCT01696643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02337569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02
Study NCT02337569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03146065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Comparison of different dosages of PF-06730512 to Placebo
Study NCT03146065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of Placebo to different doses of PF-06730512
Study NCT00362869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days
Study NCT00362869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days
Study NCT00362869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate solution
Study NCT00362869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium bicarbonate solution
Study NCT00362869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enteroaggregative E. coli (EAEC)
Description: Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
Study NCT03329066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAST - Managing Asthma & Sleep in Teens
Description: This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
Study NCT03329066 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASMA - Asthma Self-Management for Adol
Description: This behavioral intervention focuses only on asthma care.
Study NCT03329066 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information & Referral Control Group
Description: Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
Study NCT01833364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of the Peripheral Nerve Graft
Description: The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility.
Study NCT02886858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device : Transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
Study NCT02886858 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device : sham Transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
Study NCT01872403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel/carboplatin
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
Study NCT01435395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, bevacizumab and bortezomib
Description: Escalating temozolomide with standard dose bevacizumab and bortezomib
Study NCT01801410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
Study NCT01801410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 25mcg every 2 hours for maximum of 12 doses
Study NCT02368171 — intervention group
Intervention type: OTHER
Intervention: measure exhaled carbon monoxide and nitric oxide
Study NCT00882206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
Study NCT03913260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC
Study NCT03913260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffer Matrix (No LY3375880)
Description: Administered SC
Study NCT03258346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
Study NCT03913260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix
Study NCT03913260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix
Study NCT03913260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Syringe
Description: Manual syringe used to inject LY3375880
Study NCT04049916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine Tetraphosphate/Artesunate
Description: Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
Study NCT04049916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine Tetraphosphate/Artesunate
Description: Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
Study NCT00799422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Description: Commercially marketed contact lens solution for contact lens care
Study NCT00799422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
Study NCT01104584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
Study NCT04049916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: H. pylori eradication therapy
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: H. pylori eradication therapy
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: H. pylori eradication therapy
Study NCT02466919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: H. pylori eradication therapy
Study NCT04049916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine Diphosphate
Description: Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.